Q-omics provides the consensus-scored MAPK4 profile across patient tissues and cancer cell-line models. MAPK4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, MAPK4 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MAPK4 RNA expression shows 15,695 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, KIRC, and TGCT as cancer lineages where MAPK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK4 survival associations across molecular data types. MAPK4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK4 RNA expression–survival associations across cancer types. High MAPK4 expression shows unfavorable associations in LGG, SKCM, LUSC and LUAD, but favorable associations in ACC and KIRP. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for MAPK4 RNA expression.
This table summarizes MAPK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MAPK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK4 shows lower tumor expression in KIRC, THCA, BLCA, KIRP, COAD and LUAD. The KIRC box plot shows higher MAPK4 RNA expression in normal versus tumor tissue (log2 FC = −2.675, t-test p < 0.001).
This table shows molecular features associated with MAPK4 in patient tissues and cancer cell lines. In patient samples, MAPK4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAPK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and SKIN.
